A collaboration in COVID-19 between immunology specialist Vir Biotechnology (Nasdaq: VIR) and Alnylam Pharmaceuticals (Nasdaq: ALNY) has begun to bear fruit.
The firms have picked an investigational RNAi therapeutic candidate, VIR-2703 (or ALN-COV), to take further as an inhalable formulation for treating or preventing COVID-19.
An existing collaboration between the companies was extended in March to include the new target, with Vir agreeing to lead all development and commercialization of any selected development candidates.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze